Skip to content

Company
Pipeline
For Investors
Contact

Company
Pipeline
For Investors
Contact

Press Releases

Choose Year
Search Press Releases

Found 269 Results

February 2, 2016

Relmada Therapeutics to Present at the 18th Annual BIO CEO & Investor Conference

January 26, 2016

Relmada Therapeutics Files Amended Complaint Against Laidlaw and Its Principals, Matthew Eitner and James Ahern

January 11, 2016

Relmada Therapeutics Selected to Present at 2016 Biotech Showcase™ in San Francisco

January 4, 2016

Relmada Therapeutics Successfully Completes Multiple Ascending Dose Study of d-Methadone for Neuropathic Pain

December 30, 2015

Relmada Therapeutics Announces Results of Annual Meeting of Stockholders

December 28, 2015

Relmada Therapeutics Recommends Stockholders Vote “FOR” Relmada’s Director Nominees on the WHITE Proxy Card Today

December 23, 2015

U.S. Federal Court Grants Preliminary Injunction Against Laidlaw & Company and its Principals Matthew Eitner and James Ahern

December 21, 2015

Relmada Sends Letter To Stockholders Highlighting Significant Progress In Value Creation Strategy Overseen By Board And Management Team

December 15, 2015

Leading Independent Proxy Advisory Firm Glass Lewis Recommends Relmada Stockholders Vote the WHITE Proxy Card “FOR” Relmada’s Director Nominees: Shreeram Agharkar and Maged Shenouda

December 14, 2015

Pharmaceutical Industry Leader James Dolan Joins Relmada Therapeutics Advisory Team

«...19 202122 23 24...»

IR Contact

Brian Ritchie
LifeSci Advisors, LLC

+1 (212) 915-2578
britchie@lifesciadvisors.com

Email Alerts Sign-Up

Email

I accept the Privacy Policy^*

Unsubscribe

Loading...

Company

Pipeline
Overview
NDV-01
Speranolone

For Investors
Summary
News
Events
SEC Filings
Corporate Governance
Stock Information

Contact

info@relmada.com

+1 (786) 629-1376

©2026 Relmada Therapeutics, Inc.

Privacy Policy
Terms of Use

Scroll to Top